|
1
|
Wang ZX, Cao JX, Liu ZP, Cui YX, Li CY, Li
D, Zhang XY, Liu JL and Li JL: Combination of chemotherapy and
immunotherapy for colon cancer in China: A meta-analysis. World J
Gastroenterol. 20:1095–1106. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Sears CL and Garrett WS: Microbes,
microbiota, and colon cancer. Cell Host Microbe. 15:317–328. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Magalhães B, Peleteiro B and Lunet N:
Dietary patterns and colorectal cancer: Systematic review and
meta-analysis. Eur J Cancer Prev. 21:15–23. 2012. View Article : Google Scholar
|
|
4
|
Mantovani A: Cancer: Inflaming metastasis.
Nature. 457:36–37. 2009. View
Article : Google Scholar : PubMed/NCBI
|
|
5
|
Hanahan D and Weinberg RA: Hallmarks of
cancer: The next generation. Cell. 144:646–674. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Julémont F, Dogné JM, Pirotte B and de
Leval X: Recent development in the field of dual COX/5-LOX
inhibitors. Mini Rev Med Chem. 4:633–638. 2004. View Article : Google Scholar
|
|
7
|
Harris RE: Cyclooxygenase-2 (cox-2)
blockade in the chemoprevention of cancers of the colon, breast,
prostate, and lung. Inflammopharmacology. 17:55–67. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
DuBois RN, Giardiello FM and Smalley WE:
Nonsteroidal anti-inflammatory drugs, eicosanoids, and colorectal
cancer prevention. Gastroenterol Clin North Am. 25:773–791. 1996.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Perumal V, Banerjee S, Das S, Sen RK and
Mandal M: Effect of liposomal celecoxib on proliferation of colon
cancer cell and inhibition of DMBA-induced tumor in rat model.
Cancer Nanotechnol. 2:67–79. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Tavolari S, Munarini A, Storci G, Laufer
S, Chieco P and Guarnieri T: The decrease of cell membrane fluidity
by the non-steroidal anti-inflammatory drug Licofelone inhibits
epidermal growth factor receptor signalling and triggers apoptosis
in HCA-7 colon cancer cells. Cancer Lett. 321:187–194. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Balansky R, Ganchev G, Iltcheva M, Nikolov
M, Maestra SL, Micale RT, D'Agostini F, Steele VE and De Flora S:
Modulation by licofelone and celecoxib of experimentally induced
cancer and preneoplastic lesions in mice exposed to cigarette
smoke. Curr Cancer Drug Targets. 15:188–195. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Wang D and Dubois RN: Eicosanoids and
cancer. Nat Rev Cancer. 10:181–193. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Greene ER, Huang S, Serhan CN and
Panigrahy D: Regulation of inflammation in cancer by eicosanoids.
Prostaglandins Other Lipid Mediat. 96:27–36. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Mohammed A, Janakiram NB, Li Q, Choi CI,
Zhang Y, Steele VE and Rao CV: Chemoprevention of colon and small
intestinal tumorigenesis in APCMin/+ mice by licofelone,
a novel dual 5-LOX/COX inhibitor: Potential implications for human
colon cancer prevention. Cancer Prev Res. 4:2015–2026. 2011.
View Article : Google Scholar
|
|
15
|
Tavolari S, Bonafè M, Marini M, Ferreri C,
Bartolini G, Brighenti E, Manara S, Tomasi V, Laufer S and
Guarnieri T: Licofelone, a dual COX/5-LOX inhibitor, induces
apoptosis in HCA-7 colon cancer cells through the mitochondrial
pathway independently from its ability to affect the arachidonic
acid cascade. Carcinogenesis. 29:371–380. 2008. View Article : Google Scholar
|
|
16
|
Acosta KB, Tibolla MM, Tiscornia MM,
Lorenzati MA and Zapata PD: Recent patents related to
phosphorylation signaling pathway on cancer. Recent Pat DNA Gene
Seq. 5:175–184. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Hu H, Krasinskas A and Willis J:
Perspectives on current tumor-node-metastasis (TNM) staging of
cancers of the colon and rectum. Semin Oncol. 38:500–510. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Zhu LB, Jiang J, Zhu XP, Wang TF, Chen XY,
Luo QF, Shu Y, Liu ZL and Huang SH: Knockdown of Aurora-B inhibits
osteosarcoma cell invasion and migration via modulating
PI3K/Akt/NF-κB signaling pathway. Int J Clin Exp Pathol.
7:3984–3991. 2014.
|
|
19
|
Coussens LM and Werb Z: Inflammation and
cancer. Nature. 420:860–867. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Vakkila J and Lotze MT: Inflammation and
necrosis promote tumour growth. Nat Rev Immunol. 4:641–648. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Agarwal S, Reddy GV and Reddanna P:
Eicosanoids in inflammation and cancer: The role of COX-2. Expert
Rev Clin Immunol. 5:145–165. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Balkwill F and Mantovani A: Inflammation
and cancer: Back to Virchow? Lancet. 357:539–545. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Harris RE, Chlebowski RT, Jackson RD, Frid
DJ, Ascenseo JL, Anderson G, Loar A, Rodabough RJ, White E and
McTiernan A; Women's Health Initiative: Breast cancer and
nonsteroidal anti-inflammatory drugs: Prospective results from the
Women's Health Initiative. Cancer Res. 63:6096–6101.
2003.PubMed/NCBI
|
|
24
|
Wang MT, Honn KV and Nie D:
Cyclooxygenases, prostanoids, and tumor progression. Cancer
Metastasis Rev. 26:525–534. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Dubois RN, Abramson SB, Crofford L, Gupta
RA, Simon LS, Van De Putte LB and Lipsky PE: Cyclooxygenase in
biology and disease. FASEB J. 12:1063–1073. 1998.PubMed/NCBI
|
|
26
|
Eberhart CE, Coffey RJ, Radhika A,
Giardiello FM, Ferrenbach S and DuBois RN: Up-regulation of
cyclooxygenase 2 gene expression in human colorectal adenomas and
adenocarcinomas. Gastroenterology. 107:1183–1188. 1994.PubMed/NCBI
|
|
27
|
Ashok V, Dash C, Rohan TE, Sprafka JM and
Terry PD: Selective cyclooxygenase-2 (COX-2) inhibitors and breast
cancer risk. Breast. 20:66–70. 2011. View Article : Google Scholar
|
|
28
|
Ferrandina G, Lauriola L, Zannoni GF,
Fagotti A, Fanfani F, Legge F, Maggiano N, Gessi M, Mancuso S,
Ranelletti FO, et al: Increased cyclooxygenase-2 (COX-2) expression
is associated with chemotherapy resistance and outcome in ovarian
cancer patients. Ann Oncol. 13:1205–1211. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Gupta S, Srivastava M, Ahmad N, Bostwick
DG and Mukhtar H: Overexpression of cyclooxygenase-2 in human
prostate adenocarcinoma. Prostate. 42:73–78. 2000. View Article : Google Scholar
|
|
30
|
Hida T, Yatabe Y, Achiwa H, Muramatsu H,
Kozaki K, Nakamura S, Ogawa M, Mitsudomi T, Sugiura T and Takahashi
T: Increased expression of cyclooxygenase 2 occurs frequently in
human lung cancers, specifically in adenocarcinomas. Cancer Res.
58:3761–3764. 1998.PubMed/NCBI
|
|
31
|
Pidgeon GP, Lysaght J, Krishnamoorthy S,
Reynolds JV, O'Byrne K, Nie D and Honn KV: Lipoxygenase metabolism:
Roles in tumor progression and survival. Cancer Metastasis Rev.
26:503–524. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Ye YN, Wu WK, Shin VY, Bruce IC, Wong BC
and Cho CH: Dual inhibition of 5-LOX and COX-2 suppresses colon
cancer formation promoted by cigarette smoke. Carcinogenesis.
26:827–834. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Bishnoi M, Patil CS, Kumar A and Kulkarni
SK: Protective effects of nimesulide (COX inhibitor), AKBA (5-LOX
inhibitor), and their combination in aging-associated abnormalities
in mice. Methods Find Exp Clin Pharmacol. 27:465–470. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Pommery N, Taverne T, Telliez A, Goossens
L, Charlier C, Pommery J, Goossens JF, Houssin R, Durant F and
Hénichart JP: New COX-2/5-LOX inhibitors: Apoptosis-inducing agents
potentially useful in prostate cancer chemotherapy. J Med Chem.
47:6195–6206. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Smyth EM, Grosser T, Wang M, Yu Y and
FitzGerald GA: Prostanoids in health and disease. J Lipid Res.
50(Suppl): S423–S428. 2009. View Article : Google Scholar :
|
